GLI1 and familial pancreatic carcinoma: As direct inhibition of Gli expression by siRNA or by the Gli inhibitor Gant61 has been shown to block pancreatic cancer cell growth and survival [40], Gli1 could be considered a ‘druggable’ therapeutic target in the Hh pathway, downstream of Smo [21].